Vertex [VRTX] vs Insmed [INSM] Detailed Stock Comparison

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

Insmed Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Vertex Pharmaceuticals Inc. wins in 18 metrics, Insmed Inc. wins in 1 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Vertex Pharmaceuticals Inc. Insmed Inc. Better
P/E Ratio (TTM) 28.40 -22.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 5.92 40.88 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 10.91 101.43 Vertex Pharmaceuticals Inc.
PEG Ratio 0.88 -1.34 Vertex Pharmaceuticals Inc.
EV/EBITDA 21.78 -30.30 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 32.94% -210.54% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 39.60% -94.64% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) 39.60% N/A N/A
Return on Equity 22.54% -249.28% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) 12.16% -28.99% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $3.19B $-967.58M Vertex Pharmaceuticals Inc.
1-Year Return -2.31% -0.89% Insmed Inc.
Price-to-Sales Ratio (TTM) 9.22 50.18 Vertex Pharmaceuticals Inc.
Enterprise Value $105.96B $29.71B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 8.83 48.99 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) 85.39% 83.24% Vertex Pharmaceuticals Inc.
Revenue per Share (TTM) $47 $3 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $15.32 $-6.35 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.37 1.10 Vertex Pharmaceuticals Inc.
Short % of Float 1.78% 7.19% Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. vs Insmed Inc. Stock Performance Analysis

Loading Price Chart...

VRTX
INSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vertex Pharmaceuticals Inc.1.24%1.69%3.09%-3.36%-1.15%-0.37%
Insmed Inc.-0.40%3.49%-10.70%-32.60%-50.51%-44.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vertex Pharmaceuticals Inc.-2.31%27.89%136.85%413.01%888.51%1,245.83%
Insmed Inc.-0.89%389.25%236.25%934.36%717.46%614.23%

Performance & Financial Health Analysis: Vertex Pharmaceuticals Inc. vs Insmed Inc.

MetricVRTXINSM
Market Information
Market Cap i$109.45B$31.05B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,057,0611,921,156
90 Day Avg. Volume i1,272,0972,308,299
Last Close$450.46$97.46
52 Week Range$362.50 - $507.92$90.39 - $212.75
% from 52W High-11.31%-54.19%
All-Time High$519.88 (Nov 04, 2024)$212.81 (Dec 02, 2025)
% from All-Time High-13.35%-54.20%
Growth Metrics
Quarterly Revenue Growth0.10%1.53%
Quarterly Earnings Growth0.31%1.53%
Financial Health
Profit Margin (TTM) i0.33%-2.11%
Operating Margin (TTM) i0.40%-0.95%
Return on Equity (TTM) i0.23%-2.49%
Debt to Equity (MRQ) i10.91101.43
Cash & Liquidity
Book Value per Share (MRQ)$73.49$3.45
Cash per Share (MRQ)$26.01$6.63
Operating Cash Flow (TTM) i$3.63B$-935,014,016
Levered Free Cash Flow (TTM) i$2.57B$-534,054,880
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vertex Pharmaceuticals Inc. vs Insmed Inc.

MetricVRTX (Apr 26, 2026)INSM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i28.40-22.40
Forward P/E i19.95188.19
PEG Ratio i0.88-1.34
Price to Sales (TTM) i9.2250.18
Price to Book (MRQ) i5.9240.88
Market Capitalization
Market Capitalization i$109.45B$31.05B
Enterprise Value i$105.96B$29.71B
Enterprise Value Metrics
Enterprise to Revenue i8.8348.99
Enterprise to EBITDA i21.78-30.30
Risk & Other Metrics
Beta i0.371.10
Book Value per Share (MRQ) i$73.49$3.45

Financial Statements Comparison: Vertex Pharmaceuticals Inc. vs Insmed Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVRTX (2025)INSM (2025)
Revenue/Sales i12.00B606.42M
Cost of Goods Sold i1.65B122.94M
COGS % of Revenue i13.8%20.3%
Gross Profit i10.35B483.49M
Gross Margin i86.2%79.7%
Research & Development i4.04B771.09M
Operating Income (EBIT) i4.55B-994.78M
Operating Margin i37.9%-164.0%
EBITDA i5.25B-986.38M
EBITDA Margin i43.7%-162.7%
Pre-Tax Income i4.64B-1.27B
Pre-Tax Income % of Revenue i38.7%-209.7%
Income Tax i690.00M5.03M
Income Tax % of Revenue i5.7%0.8%
Net Income (Profit) i3.95B-1.28B
Profit Margin i32.9%-210.5%

Balance Sheet & Liquidity Metrics

MetricVRTX (2025)INSM (2025)
Cash & Equivalents i5.08B510.45M
Total Current Assets i11.20B1.79B
Total Current Assets % of Revenue i93.3%295.9%
Total Current Liabilities i3.86B468.87M
Total Current Liabilities % of Revenue i32.2%77.3%
Long-Term Debt i1.95B573.86M
Long-Term Debt % of Revenue i16.3%94.6%
Total Shareholders Equity i18.67B738.98M
Retained Earnings i13.56B-5.64B
Retained Earnings % of Revenue i113.0%-929.5%
Property, Plant & Equipment i1.56B76.73M

Cash Flow Statement Comparison

MetricVRTX (2025)INSM (2025)
Operating Cash Flow i3.77B-943.31M
Operating Cash Flow % of Revenue i31.4%-155.6%
Capital Expenditures i-437.60M-32.56M
Free Cash Flow i3.19B-967.58M
FCF Margin i26.6%-159.6%
Debt Repayment i-5.40M-4.93M
Common Stock Repurchase i-2.39BN/A

Short Interest & Institutional Ownership Analysis

MetricVRTXINSM
Shares Short i4.02M13.76M
Short Ratio i2.805.69
Short % of Float i1.78%7.19%
Shares Outstanding i253.99M214.26M
Float Shares i253.24M193.23M
% Held by Insiders i0.21%0.55%
% Held by Institutions i97.60%102.57%
% Held by Public i2.19%-3.12%

Dividend Analysis & Yield Comparison: Vertex Pharmaceuticals Inc. vs Insmed Inc.

MetricVRTXINSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A